abevmy
biosimilar collaborations ireland limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiska medel - abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. för vidare information om human epidermal growth factor receptor 2 (her2) status, se avsnitt 5. abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with abevmy in combination with capecitabine. för ytterligare information om her2-status, se avsnitt 5. abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics [figo] stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.
saphnelo
astrazeneca ab - anifrolumab - lupus erythematosus, systemic - immunsuppressiva - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.
sorafenib accord
accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastiska medel - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
ribavirin sandoz 200 mg kapsel, hård
sandoz a/s - ribavirin - kapsel, hård - 200 mg - mannitol hjälpämne; propylenglykol hjälpämne; ribavirin 200 mg aktiv substans - ribavirin
copegus 200 mg filmdragerad tablett
roche ab - ribavirin - filmdragerad tablett - 200 mg - natriumlaurilsulfat hjälpämne; ribavirin 200 mg aktiv substans; cetylalkohol hjälpämne - ribavirin
moderiba 200 mg filmdragerad tablett
abbvie ab - ribavirin - filmdragerad tablett - 200 mg - ribavirin 200 mg aktiv substans; laktosmonohydrat hjälpämne - ribavirin
copegus 400 mg filmdragerad tablett
roche ab - ribavirin - filmdragerad tablett - 400 mg - ribavirin 400 mg aktiv substans - ribavirin
moderiba 400 mg filmdragerad tablett
abbvie ab - ribavirin - filmdragerad tablett - 400 mg - ribavirin 400 mg aktiv substans; laktosmonohydrat hjälpämne - ribavirin
moderiba 600 mg filmdragerad tablett
abbvie ab - ribavirin - filmdragerad tablett - 600 mg - ribavirin 600 mg aktiv substans; laktosmonohydrat hjälpämne - ribavirin
trinomia 100 mg/20 mg/10 mg kapsel, hård
ferrer internacional, sa. - acetylsalicylsyra; atorvastatinkalciumtrihydrat; ramipril - kapsel, hård - 100 mg/20 mg/10 mg - laktosmonohydrat hjälpämne; acetylsalicylsyra 50 mg aktiv substans; acetylsalicylsyra 50 mg aktiv substans; atorvastatinkalciumtrihydrat 10,845 mg aktiv substans; propylenglykol hjälpämne; ramipril 10 mg aktiv substans; atorvastatinkalciumtrihydrat 10,845 mg aktiv substans; sojalecitin hjälpämne - acetylsalicylsyra och ramipril